Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities

Higo, Hisao; Kubo, Toshio; Makimoto, Satoko; Makimoto, Go; Ihara, Hidetoshi; Masaoka, Yoshihisa; Ninomiya, Takashi; Ichihara, Eiki; Ohashi, Kadoaki; Satô, Akiko; Hotta, Katsuyuki; Tabata, Masahiro; Takigawa, Nagio; Maeda, Yoshinobu; Kiura, Katsuyuki

doi:10.1093/jjco/hyz016

Cited by 21 publications

(21 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ILA may be of similar importance as ILD in predicting RRP because a part of ILA was reported to proceed as ILD 16 . Although previous studies reported unfavorable impact of ILA on RP in patients with lung cancer receiving thoracic radiotherapy, their study cohorts were heterogeneous population with tumor stage, total radiation dose, chemotherapy regimen or timing of radiotherapy 17,18 . In contrast in this study, most patients received treatment were etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy which is standard treatment recommended by The Japanese Lung Cancer Society Guideline 2019 15 .…”

Section: Discussionmentioning

confidence: 99%

Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer and Interstitial Lung Abnormalities

Kobayashi

Wakuda

Naito

et al. 2020

Preprint

View full text Add to dashboard Cite

Purpose: Patients with lung cancer and interstitial lung disease treated with radiotherapy have been reported to be at a risk of developing radiation pneumonitis. However, the association between interstitial lung abnormalities (ILA) and radiation pneumonitis in patients with limited-stage small cell lung cancer (LS-SCLC) remains unclear. Furthermore, the prognosis is unclear for patients with SCLC and ILA treated with chemoradiotherapy. We investigated the impact of ILA on radiation pneumonitis and assessed the prognosis of patients with LS-SCLC and ILA treated chemoradiotherapy. Methods and materials: We retrospectively reviewed the medical records of 149 patients with LS-SCLC who received first-line treatment between January 2009 and December 2016. Results: In a univariate analysis, the patients with ILA showed a higher incidence rate of radiation pneumonitis compared with those without ILA (64% vs. 10%); multivariate analysis confirmed that ILA was significantly associated with the incidence of radiation pneumonitis. In the univariate analysis, patients with ILA showed poorer overall survival than those without ILA (median, 18.9 vs. 67.9 months). Multivariate analysis showed that ILA was a significant independent negative prognostic factor. However, the 2-year and 5-year survival rates for the patients with ILA treated with chemoradiotherapy were 36% and 26%, respectively; for those treated with chemotherapy alone were 8% and 0%, respectively.Conclusions: ILA was a predictive factor for radiation pneumonitis in patients with LS-SCLC treated with chemoradiotherapy. The prognosis of the patients with LS-SCLC and ILA was poor; however, some patients with ILA treated chemoradiotherapy achieved long-term survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer and Interstitial Lung Abnormalities

Kobayashi

Wakuda

Naito

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…The authors suggest that a UIP pattern on CT imaging may be a major risk factor for acute exacerbation of ILD. 6 Higo et al 7 retrospectively reviewed their experience with patients receiving chemoradiotherapy for LA-NSCLC. Of 77 patients, ILAs were present in 25 (32.5%), indeterminate in 24 (31%), and not present in 28 (36%).…”

Section: Rt and Coexisting Ild In Locally Advanced Lung Cancermentioning

confidence: 99%

“…Two-year survival rates (56.8% and 74.1% for patients with and without ILA, respectively) were not significantly different. 7…”

Section: Rt and Coexisting Ild In Locally Advanced Lung Cancermentioning

confidence: 99%

“…[1][2][3][4] Emerging evidence suggests that patients with ILD undergoing any treatment, including thoracic radiotherapy (TRT), are at a higher risk of treatmentrelated toxicities, compounding their baseline risk of morbidity from life-threatening ILD exacerbations. [5][6][7][8][9] Thus, patients with concomitant diagnoses of ILD and lung cancer represent a unique challenge in oncologic management. Despite the urgent need for cancer therapy, any treatment requires careful consideration of patient-, ILD-, and cancer-specific factors.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Primer on Interstitial Lung Disease and Thoracic Radiation

Goodman

Nijman

Senan

et al. 2020

Journal of Thoracic Oncology

View full text Add to dashboard Cite

Interstitial lung disease (ILD) is a term used to describe a heterogeneous group of lung disorders with characteristic clinical and imaging features. Patients with ILD are at an increased risk of developing NSCLC, which is frequently medically comorbid, often precluding operative management. In this scenario, radiotherapy (RT) is generally recommended; however, ILD is known to increase the risk of RT-related toxicity. Recommendations for treatment with appropriately individualized risks and benefits are thus dependent on integration of patient-, ILD-, and cancerspecific factors. We aim to provide an overview of ILD for the thoracic oncologist, an assessment of risk of thoracic RT in patients with ILD, and evidence-based recommendations for treatment in a variety of clinical scenarios.

show abstract

“…Многие авторы подчеркивают, что у пациентов с МИИ достоверно чаще развивается РДС, а также рак легкого и осложнения разных вариантов его лечения (оперативного, лучевой, химиотерапии) [15][16][17][18][19][20][21][22].…”

unclassified

Radiological and Morphological Patterns of Idiopathic Pulmonary Fibrosis From the Earliest Manifestations to the Outcome

Сперанская

Novikova

Dvorakovskaia

et al. 2020

Lučevaâ diagn. ter.

View full text Add to dashboard Cite

Первый Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова, Санкт-Петербург, Россия Цель. Оценить изменение лучевой и морфологической картины фиброзирующих болезней легких (ФБЛ) при их длительном наблюдении. Материалы и методы. Проанализированы данные 676 больных ФБЛ, возраст 53,3±15,2 года (ж/м-412/264). Выполнены ВРКТ, ОФЭКТ, КИФВД (с ДСЛ), эхокардиография. Результаты. ОИП у 142 больных (21,0%, ДСЛ менее 30% от Д) характеризовалась на КТ и ОФЭКТ нарастанием размеров и распространенности «сот», появлением новых субплевральных участков «матового стекла» и их трансформацией в «соты», выраженным снижением микроциркуляции в легких. НСИП у 439 пациентов (64,9%, ДСЛ-50% от Д) на КТ и ОФЭКТ проявлялась субплевральными ретикулярными изменениями и «матовым стеклом» без «сотового легкого», трансформировались в «соты». Обострение ФБЛ у 24 пациентов (3,5%) на КТ, ОФЭКТ и гистологически проявлялось ОсИП и КОП. У 11 больных привело к прогрессированию фиброза. Ранние признаки ФБЛ у 32 больных (4,7%, ДСЛ 70% от Д) на КТ, ОФЭКТ и морфологии проявлялись минимальными изменениями, трансформировались в картину ФБЛ у 21 пациента. Заключение. Накопление опыта клинико-лучевого обследования пациентов с ФБЛ обусловливает необходимость разработки новых подходов в диагностической и лечебной тактике. Ключевые слова: компьютерная томография, морфология, микроциркуляция, идиопатический легочный фиброз Контакт: Сперанская Александра Анатольевна,

show abstract

Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities

Cited by 21 publications

References 31 publications

Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer and Interstitial Lung Abnormalities

Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer and Interstitial Lung Abnormalities

A Primer on Interstitial Lung Disease and Thoracic Radiation

Radiological and Morphological Patterns of Idiopathic Pulmonary Fibrosis From the Earliest Manifestations to the Outcome

Contact Info

Product

Resources

About